Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy.
about
A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patientsCross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patientsLearning from biomedical linked data to suggest valid pharmacogenes.Distinctions in gastric cancer gene expression signatures derived from laser capture microdissection versus histologic macrodissectionmiRNA signature associated with outcome of gastric cancer patients following chemotherapy.EPMA position paper in cancer: current overview and future perspectives.FGFR2 gene amplification and clinicopathological features in gastric cancerAn individualized prognostic signature for gastric cancer patients treated with 5-Fluorouracil-based chemotherapy and distinct multi-omics characteristics of prognostic groups.Gastric cancer-molecular and clinical dimensions.Fibroblast growth factors and their receptors in cancer.Fibroblast growth factor receptor 2: a therapeutic target in gastric cancer.Predictive biomarker candidates for the response of gastric cancer to targeted and cytotoxic agents.Integrated Proteomic and Genomic Analysis of Gastric Cancer Patient Tissues.Therapeutic targeting of fibroblast growth factor receptors in gastric cancer.Gastric cancer and gene copy number variation: emerging cancer drivers for targeted therapy.In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients.Stem Cells Antigen-1 Enriches for a Cancer Stem Cell-Like Subpopulation in Mouse Gastric Cancer.High STMN1 level is associated with chemo-resistance and poor prognosis in gastric cancer patients.Establishment and characterization of metastatic gastric cancer cell lines from murine gastric adenocarcinoma lacking Smad4, p53, and E-cadherin.Overexpression of miR-17 in gastric cancer is correlated with proliferation-associated oncogene amplification.Gene-expression profiling to predict responsiveness to immunotherapy.MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors.Multi-omics landscapes of colorectal cancer subtypes discriminated by an individualized prognostic signature for 5-fluorouracil-based chemotherapy.Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.Methylation of the HOXA10 promoter directs miR-196b-5p dependent cell proliferation and invasion of gastric cancer cells.CONCORD biomarker prediction for novel drug introduction to different cancer types.LTBP2 promotes the migration and invasion of gastric cancer cells and predicts poor outcome of patients with gastric cancer.ADRM1 gene amplification is a candidate driver for metastatic gastric cancers.Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin).
P2860
Q28477202-8524BCC8-4DCD-4BC3-92E6-389416EF98C9Q31112933-AA0192A2-0D78-43FC-B3F5-875C26652BF4Q33587530-80694E9C-CDB1-47AA-B1E9-51E0CCACBC29Q33920296-49C823A7-70FB-47BA-A305-A46799BBF32BQ34082270-50F98957-1B8A-44CC-ACE3-0D8156B48240Q35532215-470D1683-2D9E-4A94-9D9C-04886D6AF36FQ35879874-552A4A61-3A4F-4AF5-A4C5-F4ACEAB07D76Q36962398-FC50EAE5-53B2-4877-9FD7-50F91F85009AQ37591176-1222A81A-E1E1-4855-B0BA-2B8FB08CC7BFQ37895306-5DD283D8-23CF-4DB1-A2C3-313E744BA965Q38153418-CF27D8E8-84A3-4AA8-8298-F1AFB419093BQ38188598-23629F64-CA40-4B39-BA48-79F3214DC616Q38402575-BB62E943-F6BC-4FEB-9EBE-96657F46C773Q38497265-796A391A-063F-48CC-90B7-883097A2A5A4Q38527414-17C3F400-6AA6-4DED-A206-C3C78B77924FQ38602669-A8BD4FC7-D8DF-46F9-83A0-DE2029759971Q38794864-E5F26E2B-3E04-41FA-8DE0-8DA3CDBD39E5Q38882319-C0064785-0733-4497-B333-6924279B7923Q38948732-0E4F1400-CBBE-4E9D-B8D7-6CFB529ACC89Q38973216-61973AB6-D8B3-4595-803D-701E486FA99FQ39005203-DD7048A4-2235-4C40-9062-712FB26F86A0Q39372689-94010713-EEAA-4090-8027-F5F8E9082F60Q39590420-B3C2848E-2C37-4B82-B11D-2D816F135DD9Q48168816-9E9D0413-C43A-44B5-9E18-D4E754B7738FQ49913610-9AD78DF7-E5A0-456B-81DB-EFD244FAAB62Q50128212-74FCCBAD-7F2B-4001-B899-3D007EC03892Q52605309-3032ADD1-C05C-400C-9425-0310E2324E5DQ53038879-70EE756C-2C9A-46EF-955B-09D987DEBA87Q53167144-30EA9204-4107-4D69-88C0-21C7546A44C7
P2860
Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Three-gene predictor of clinic ...... nts treated with chemotherapy.
@ast
Three-gene predictor of clinic ...... nts treated with chemotherapy.
@en
type
label
Three-gene predictor of clinic ...... nts treated with chemotherapy.
@ast
Three-gene predictor of clinic ...... nts treated with chemotherapy.
@en
prefLabel
Three-gene predictor of clinic ...... nts treated with chemotherapy.
@ast
Three-gene predictor of clinic ...... nts treated with chemotherapy.
@en
P2093
P2860
P356
P1476
Three-gene predictor of clinic ...... nts treated with chemotherapy.
@en
P2093
A Michalowski
P2860
P2888
P304
P356
10.1038/TPJ.2010.87
P577
2010-12-21T00:00:00Z